Anti-CD20 IgA can protect mice against lymphoma development: Evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells

Haematologica

Volumn 97, Issue 11, 2012, Pages 1686-1694

  Pascal, Virginie ^a   Laffleur, Brice ^a   Debin, Arnaud ^b   Cuvillier, Armelle ^c   van Egmond, Marjolein ^d   Drocourt, Daniel ^b   Imbertie, Laurent ^b   Pangault, Céline ^e   Tarte, Karin ^e   Tiraby, Gérard ^b   Cogné, Michel ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b Zone industrielle de Montaudran   (France)

^c B Cell Design   (France)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e INSERM U917   (France)

Author keywords

Anti CD20 IgA; F RI; Lymphoma

Indexed keywords

CD16 ANTIGEN; CD20 ANTIBODY; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G1 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LEUKOCYTE; LYMPHOMA; MOUSE; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, CD20; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; JURKAT CELLS; LYMPHOMA; MICE; MICE, TRANSGENIC; NEUTROPHIL INFILTRATION; NEUTROPHILS; RECEPTORS, FC;

EID: 84868581337     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.061408     Document Type: Article

References (44)

1. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class Irelated receptor FcRn. Annu Rev Immunol. 2000;18:739-66.
2. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med. 1987; 166(5):1351-61.
3. Pakkanen SH, Kantele JM, Moldoveanu Z, Hedges S, Hakkinen M, Mestecky J, et al. Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin Vaccine Immunol. 2010;17(3):393-401.
4. Mostov KE. Transepithelial transport of immunoglobulins. Annu Rev Immunol. 1994;12:63-84.
5. Daha MR, Gorter A, Rits M, van Es LA, Hiemstra PS. Interaction of immunoglobulin A with complement and phagocytic cells. Prog Clin Biol Res. 1989;297:247-60; discussion 60-1.
6. Lohse S, Peipp M, Beyer T, Valerius T, Dechant M. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-Rdirected antibodies. Arch Immunol Ther Exp (Warsz). 2010;58(4):303-12.
7. Jarvis GA, Griffiss JM. Human IgA1 initiates complement-mediated killing of Neisseria meningitidis. J Immunol. 1989;143(5):1703-9.
8. Hiemstra PS, Gorter A, Stuurman ME, Van Es LA, Daha MR. Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol. 1987;17(3):321-6.
9. Pfaffenbach G, Lamm ME, Gigli I. Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes. J Exp Med. 1982;155(1):231-47.
10. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001;167(5):2861-8.
11. Morton HC, van Egmond M, van de Winkel JG. Structure and function of human IgA Fc receptors (Fc alpha R). Crit Rev Immunol. 1996;16(4):423-40.
12. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol. 2003;21: 177-204.
13. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97(2):339-45.
14. Patry C, Herbelin A, Lehuen A, Bach JF, Monteiro RC. Fc alpha receptors mediate release of tumour necrosis factor-alpha and interleukin-6 by human monocytes following receptor aggregation. Immunology. 1995;86(1):1-5.
15. van Egmond M, van Vuuren AJ, Morton HC, van Spriel AB, Shen L, Hofhuis FM, et al. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood. 1999;93(12): 4387-94.
16. Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood. 1997;90(11):4485-92.
17. Huls G, Heijnen IA, Cuomo E, van der Linden J, Boel E, van de Winkel JG, et al. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. 1999;59(22):5778-84.
18. Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood. 2002;100(13):4574-80.
19. Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol. 2007;179(5):2936-43.
20. Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol. 2011;186(6): 3770-8.
21. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002;100(5):1765-73.
22. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644-52.
23. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complementmediated cell lysis. Blood. 2000;95(12): 3900-8.
24. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003; 171(3):1581-7.
25. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-8.
26. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109-14.
27. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010;70(8):3209-17.
28. Guyre CA, Gomes D, Smith KA, Kaplan JM, Perricone MA. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies. J Immunol Methods. 2008;333(1-2):51-60.
29. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6(7):1258-66.
30. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2006;208(2):270-82.
31. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-52.
32. Zhang W, Bi B, Oldroyd RG, Lachmann PJ. Neutrophil lactoferrin release induced by IgA immune complexes differed from that induced by cross-linking of fcalpha receptors (FcalphaR) with a monoclonal antibody, MIP8a. Clin Exp Immunol. 2000;121(1):106-11.
33. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2009;2(5):412-26.
34. Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 2011;186 (5):3113-9.
35. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48(12): 673-83.
36. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97(5):1392-8.
37. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol. 1997;158(10):4525-8.
38. Nauta AJ, Trouw LA, Daha MR, Tijsma O, Nieuwland R, Schwaeble WJ, et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol. 2002;32(6):1726-36.
39. Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 2009;114(26):5322-30.
40. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115(4):807-11.
41. Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol. 2005;174(9):5472-80.
42. Oortwijn BD, Roos A, van der Boog PJ, Klar-Mohamad N, van Remoortere A, Deelder AM, et al. Monomeric and polymeric IgA show a similar association with the myeloid FcalphaRI/CD89. Mol Immunol. 2007;44(5): 966-73.
43. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol. 2009; 647:195-206.
44. Beyersdorf N, Ding X, Hunig T, Kerkau T. Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft versus host disease. Blood. 2009;114(20):4575-82.